https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27000 50. A Cox multivariate regression model for LFS retained both B-other ALL subtype (hazard ratio 4·1, P = 0·0062) and MRD persistence post-HSCT (hazard ratio 3·9, P = 0·0070) as independent adverse prognostic variables. Persistent MRD could be used to direct post-HSCT therapy.]]> Sat 24 Mar 2018 07:25:49 AEDT ]]> COVID-19 vaccination in children and adolescents aged 5 years and older undergoing treatment for cancer and non-malignant haematological conditions: Australian and New Zealand Children’s Haematology/Oncology Group consensus statement https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48191 Sat 11 Mar 2023 12:30:28 AEDT ]]> Outcomes of hematopoietic stem cell transplantation in primary immunodeficiency: a report from the Australian and New Zealand children's haematology oncology group and the Australasian bone marrow transplant recipient registry https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19772 Fri 29 May 2020 17:14:37 AEST ]]>